castration-resistant prostate carcinoma
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:80909
Name castration-resistant prostate carcinoma
Definition A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer male reproductive organ cancer prostate cancer prostate carcinoma castration-resistant prostate carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PTEN loss Abiraterone + Ipatasertib castration-resistant prostate carcinoma sensitive detail...
PTEN loss Enzalutamide + GSK2636771 castration-resistant prostate carcinoma no benefit detail...
PTEN inact mut CC-115 + Enzalutamide castration-resistant prostate carcinoma predicted - sensitive detail...
PIK3CA act mut CC-115 + Enzalutamide castration-resistant prostate carcinoma predicted - sensitive detail...
PTEN N323fs Everolimus castration-resistant prostate carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03436485 Phase Ib/II ODM-208 Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer (CYPIDES) Active, not recruiting USA | GBR | FRA | FIN 0
NCT03903835 Phase III Docetaxel Cabazitaxel Carboplatin Abiraterone Enzalutamide ProBio: A Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate Cancer (ProBio) Recruiting SWE | NOR | CHE | BEL 0
NCT04104776 Phase Ib/II Enzalutamide + Tulmimetostat Tulmimetostat A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas Recruiting USA | POL | ITA | GBR | FRA | ESP 1
NCT04434482 Phase I Senaparib + Temozolomide IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer Completed USA | AUS 3
NCT04557449 Phase I Letrozole + PF-07220060 Fulvestrant + PF-07220060 Enzalutamide + PF-07220060 PF-07220060 Midazolam + PF-07220060 Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i) Recruiting USA | SVK | GBR | CZE | ARG 3
NCT04606446 Phase I PF-07248144 PF-07248144 + Vepdegestrant Fulvestrant + PF-07220060 + PF-07248144 Fulvestrant + Palbociclib + PF-07248144 Fulvestrant + PF-07248144 Letrozole + Palbociclib + PF-07248144 Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6) Recruiting USA | AUS 3
NCT04644770 Phase I JNJ-69086420 A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer Recruiting USA 0
NCT04717154 Phase II Ipilimumab + Nivolumab Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer (INSPIRE) Active, not recruiting NLD 0
NCT04839991 Phase I CB307 Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours. (POTENTIA) Recruiting USA | NLD | GBR | ESP 0
NCT04876651 Phase III Docetaxel Enzalutamide 177Lu-J591 + Abiraterone + Prednisolone Abiraterone + Prednisone 177Lu-J591 + Abiraterone + Prednisone 177Lu-J591 + Enzalutamide Abiraterone + Prednisolone 177Lu-J591 + Docetaxel The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only Recruiting NZL | AUS 0
NCT04896697 Phase Ib/II XTX101 Pembrolizumab + XTX101 XTX101 Monotherapy and XTX101 and Pembrolizumab Combination Therapy in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04926181 Phase II Apalutamide + Cetrelimab Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer Terminated USA 0
NCT04946370 Phase Ib/II Pembrolizumab 225Ac-J591 + Pembrolizumab Maximizing Responses to Anti-PD1 Immunotherapy With PSMA-targeted Alpha Therapy in mCRPC Recruiting USA 0
NCT05005728 Phase II Cabazitaxel + XmAb20717 Docetaxel + XmAb20717 XmAb20717 Olaparib + XmAb20717 Cabazitaxel + Carboplatin + XmAb20717 XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer Active, not recruiting USA 0
NCT05057013 Phase Ib/II HMBD-001 A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours Recruiting GBR 0
NCT05107674 Phase I NX-1607 A Study of NX-1607 in Adults With Advanced Malignancies Recruiting USA | GBR 0
NCT05159518 Phase I PRT2527 A Study of PRT2527 in Participants With Advanced Solid Tumors Completed USA 0
NCT05219500 Phase II FPI-2265 Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). (TATCIST) Active, not recruiting USA 0
NCT05241613 Phase I AC176 A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer Terminated USA 0
NCT05256381 Phase II Pembrolizumab + SOT101 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors Terminated USA | POL | ITA | HUN | FRA | ESP | CZE | BEL 1
NCT05272709 Phase Ib/II Darolutamide + TT-702 TT-702 TT-702 in Patients With Advanced Solid Tumours. (CURATE) Recruiting GBR 0
NCT05369000 Phase Ib/II LAVA-1207 Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer Active, not recruiting USA | NLD | ESP 0
NCT05417594 Phase Ib/II AZD9574 + Trastuzumab deruxtecan AZD9574 + Datopotamab deruxtecan AZD9574 AZD9574 + Temozolomide Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1) Recruiting USA | SWE | GBR | ESP | DEU | AUS 1
NCT05438329 Phase Ib/II DB-1305 BNT327 + DB-1305 DB-1305 + Pembrolizumab First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors Recruiting USA 2
NCT05488548 Phase I NEO2734 Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors Recruiting USA 0
NCT05501548 Phase II Olaparib Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer Terminated USA 0
NCT05534646 Phase II Apalutamide Apalutamide + Carotuximab Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer Recruiting USA 0
NCT05592626 Phase Ib/II Invikafusp alfa A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) Recruiting USA | FRA | ESP | CAN 0
NCT05655715 Phase II Ipilimumab + Nivolumab Checkpoint Inhibitors and SBRT for mCRPC (CheckPRO) Completed DNK 0
NCT05662397 Phase Ib/II HST-1011 Cemiplimab + HST-1011 A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody Active, not recruiting USA | ESP | CAN 0
NCT05689021 Phase II Niraparib and abiraterone acetate + Prednisone CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations Recruiting USA 0
NCT05700669 Phase Ib/II AsiDNA + Olaparib Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors Completed USA 0
NCT05730712 Phase II Enzalutamide + Pertuzumab/trastuzumab/hyaluronidase-zzxf Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer, TraPPer Study Active, not recruiting USA 0
NCT05762536 Phase II Docetaxel Cabazitaxel + Darolutamide Darolutamide + Docetaxel Cabazitaxel Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC (DAROTAXEL) Recruiting NLD 0
NCT05785741 Phase Ib/II DB-1310 A Phase 1/2a Study of DB-1310 in Advanced/Metastatic Solid Tumors Recruiting USA 1
NCT05818683 Phase I Cetrelimab + JNJ-78278343 A Study of JNJ-78278343 in Combination With JNJ-63723283 (Cetrelimab) for Metastatic Castration-Resistant Prostate Cancer Recruiting USA | AUS 0
NCT05841563 Phase I PM54 Clinical Trial of PM54 in Advanced Solid Tumors Patients. Recruiting USA | ESP | BEL 0
NCT05914116 Phase Ib/II DB-1311 A Study of DB-1311 in Advanced/Metastatic Solid Tumors Recruiting USA | AUS 2
NCT05917470 Phase Ib/II ONCT-534 A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. Terminated USA | GBR 0
NCT05919264 Phase Ib/II Bevacizumab + Fluorouracil + FOG-001 + Leucovorin + Oxaliplatin FOG-001 + Nivolumab FOG-001 Bevacizumab + FOG-001 + Trifluridine-tipiracil hydrochloride FOG-001 in Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05944237 Phase Ib/II Atezolizumab + HTL0039732 HTL0039732 HTL0039732 in Participants With Advanced Solid Tumours Recruiting GBR 0
NCT05983198 Phase Ib/II 225Ac-PSMA-R2 Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT (SatisfACtion) Recruiting FRA | CAN | AUS 0
NCT05999968 Phase I Abemaciclib + Darolutamide Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment Active, not recruiting USA | ESP | DEU 0
NCT06039371 Phase II Etoposide + Testosterone cypionate Carboplatin + Testosterone cypionate Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study Recruiting USA 0
NCT06126731 Phase Ib/II Amoxicillin + Enzalutamide + Metronidazole Ciprofloxacin + Enzalutamide + Vancomycin Combination Study of Antibiotics With Enzalutamide (PROMIZE) Recruiting GBR | CHE 0
NCT06136624 Phase III Dexamethasone + Fludrocortisone + ODM-208 Enzalutamide Abiraterone Study of MK-5684 Versus Alternative NHA in mCRPC (MK-5684-003) Recruiting USA | TUR | SWE | POL | NZL | NOR | NLD | ITA | ISR | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | AUT | AUS | ARG 13
NCT06136650 Phase III Abiraterone + Prednisone Dexamethasone + Fludrocortisone + ODM-208 Enzalutamide A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) Recruiting USA | TUR | SWE | SVK | ROU | NZL | LVA | LTU | ITA | ISR | IRL | HUN | GRC | GBR | FRA | EST | ESP | DEU | CZE | CAN | BRA | AUS 17
NCT06172478 Phase II Patritumab deruxtecan A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting USA | GBR | FRA | ESP | CAN | BEL | AUS 3
NCT06190899 Phase Ib/II Darolutamide + Gedatolisib Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer Recruiting USA | GBR | FRA | ESP 0
NCT06193486 Phase I MSGV1-PSCA-8T28Z Cyclophosphamide + Fludarabine Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC Recruiting USA 0
NCT06200103 FDA approved lutetium Lu 177 vipivotide tetraxetan Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Recruiting USA 0
NCT06216249 Phase II lutetium Lu 177 vipivotide tetraxetan Evaluation of a Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer Recruiting USA 0
NCT06217822 Phase I BAY3563254 First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (PAnTHA) Recruiting SWE | NLD | ITA | GBR | FIN | CHE | CAN | BEL 0
NCT06228053 Phase II Enzalutamide + SX-682 Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (SYNERGY-201) Recruiting USA 0
NCT06242470 Phase I MGC026 A Study of MGC026 in Participants With Advanced Solid Tumors Recruiting USA | GBR | AUS 0
NCT06253130 Phase Ib/II IMP1734 A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors Recruiting USA | AUS 2
NCT06305598 Phase I Leuprolide + Testosterone cypionate Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Recruiting USA 0
NCT06334432 Phase Ib/II NUV-1511 Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors Recruiting USA 0
NCT06401980 Phase II Docetaxel Radium Ra 223 dichloride 177Lu-rhPSMA-10.1 Darolutamide Olaparib Cabazitaxel Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Recruiting CHE 0
NCT06480110 Phase Ib/II Docetaxel Docetaxel + Ebastine Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer Recruiting DNK 0
NCT06492122 Phase I [225]Ac-FL-020 Study With [225Ac]Ac-FL-020 in mCRPC Participants Recruiting USA | AUS 0
NCT06531499 Phase I lutetium Lu 177 vipivotide tetraxetan A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study (RADIODOSE) Recruiting USA | NLD | GBR | ESP 0
NCT06549465 Phase II 225Ac-J591 Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer Recruiting USA 0
NCT06551324 Phase III Enzalutamide + PF-06821497 Enzalutamide Docetaxel A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). (MEVPRO-1) Recruiting USA | TUR | SWE | SVK | POL | NLD | ITA | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUS | ARG 5
NCT06560632 Phase I Olaparib + RP-3467 RP-3467 Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors (POLAR) Recruiting USA 0
NCT06576037 Phase I CBP-1019 + Enzalutamide CBP-1019 + Pembrolizumab Bevacizumab + CBP-1019 + Fluorouracil + Leucovorin + Oxaliplatin CBP-1019 + Fluorouracil + Leucovorin + Oxaliplatin Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin Recruiting USA 0
NCT06582628 Phase II Enzalutamide Enzalutamide + Talazoparib Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC) (TEAM PC) Recruiting ESP 0
NCT06592924 Phase III Enzalutamide Abiraterone Darolutamide Abiraterone + Docetaxel Apalutamide + Docetaxel Docetaxel + Enzalutamide Apalutamide Darolutamide + Docetaxel Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH) Recruiting CAN 0
NCT06609005 Phase I Dexamethasone + Fludrocortisone + INV-9956 A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer Recruiting USA 1
NCT06610825 Phase II Trastuzumab deruxtecan Castrate Resistant Prostate Cancer Enhertu Therapy (CaRPET) Recruiting USA 0
NCT06616155 Phase Ib/II Enzalutamide + Ruxolitinib Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer Recruiting USA 0
NCT06634849 Phase Ib/II PTT-4256 An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours. Recruiting AUS 0
NCT06705686 Phase I (R)-9bMS Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer (PHAROS) Not yet recruiting USA 0
NCT06725758 Phase Ib/II ODM-212 Two-part, First-in-Human Study on ODM-212 in Subjects with Selected Advanced Solid Tumours (TEADES) Recruiting GBR 0
NCT06782555 Phase Ib/II Balstilimab + Evofosfamide + Zalifrelimab A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab Recruiting USA 0
NCT06784193 Phase I OP-3136 Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors Recruiting USA | AUS 0
NCT06830850 Phase I HRS-5041 A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer Not yet recruiting AUS 0
NCT06842498 Phase II FOR46 A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Not yet recruiting USA 0
NCT06844383 Phase II Enzalutamide + Talazoparib Talazoparib A Study of Talazoparib with or Without Enzalutamide in People with Prostate Cancer Who Have Previously Received Abiraterone Acetate (TALENT) Not yet recruiting USA 0
NCT06866938 Phase II lutetium Lu 177 vipivotide tetraxetan Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer (ReaLuP) Recruiting FRA 0
NCT06894511 Phase II Enzalutamide + lutetium Lu 177 vipivotide tetraxetan lutetium Lu 177 vipivotide tetraxetan Abiraterone + lutetium Lu 177 vipivotide tetraxetan An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC (PSMAndARPI) Recruiting USA 0
NCT06907043 Phase Ib/II EIK1004 A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. (EIK1004-001) Recruiting USA 1
NCT06909825 Phase II FPI-2265 + Olaparib FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Recruiting AUS 0
NCT06925737 Phase III Docetaxel + Prednisone Ifinatamab deruxtecan A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) Recruiting USA | ISR 2
NCT06943495 Phase I lutetium Lu 177 vipivotide tetraxetan Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2) (PRODIGY-2) Not yet recruiting CAN 0
NCT06959706 Phase I TGW101 + TRG001 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors Recruiting USA 0
NCT06999187 Phase I DR-0202 A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas Recruiting USA 0
NCT07002320 Phase Ib/II Apalutamide + SX-682 Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer (ASpiRE) Recruiting GBR | CHE 0